[Brokerage Focus] China Merchants maintains a "shareholding" rating for Wuxi Bio (02269), pointing to the expansion of the animal health biopharmaceutical field that is expected to bring incremental performance.
Jingu Finance | China Merchants Securities released research reports, indicating that Wuxi Bio (02269) announced the launch of PawBio animal health biopharmaceutical one-stop solution in early November. The firm believes that as a leader in the human biopharmaceutical CDMO industry, with rich project experience, leading service quality, high customer recognition, expanding business to the field of animal biopharmaceuticals is expected to bring new business growth for the company. The firm stated that with changes in population and family structure, pets are becoming increasingly important emotional anchors and daily companions for more people. Mars Inc. recently released the global survey of pets with the largest coverage and sample data.
Medical stocks collectively surged! Bullish news has arrived, the medical sector welcomes a catalyst.
The medical sector with lagging growth finally sees a catalyst! Analysis believes that for medical institutions, prepayment of medical insurance funds helps optimize and improve the daily operation cash flow and financial pressure of medical institutions, reducing the potential receivables and bad debt risks caused by unpaid medical insurance expenses. For medical insurance, it enhances the settlement efficiency and encourages the active diagnosis and treatment enthusiasm of medical institutions.
Hong Kong stocks abnormal fluctuations | CRO concept stocks lead the gains, institutions believe that the future performance recovery is worth looking forward to. The listing of innovative drugs in the United States has demands for reducing research and d
CRO concept stocks lead the gains. As of the press release, wuxi xdc (02268) rose by 11.29% to HK$27.6; wuxi apptec (02359) fell by 4.07% to HK$58.8; wuxi bio (02269) rose by 3.09% to HK$17.34; tigermed (03347) rose by 3.05% to HK$38.9.
wuxi bio (02269.HK): Introducing a one-stop solution for animal medicine to open up new markets and contribute to incremental volume.
In early November, wuxi bio announced the launch of PawBio, a one-stop solution for animal health biologics. We believe that as a leading company in the human biologics CDMO industry, wuxi bio has rich project experience, leading service quality, and high customer recognition.
Trump Government Likely to Still Pass Biosecure Act -- Market Talk
Abnormal movements | The CRO concept is generally rising, with medical insurance negotiations supporting innovative drugs. Global biomedical financing will rebound in an environment of interest rate cuts.
The concept of CRO is generally on the rise. As of the time of publication, Asymchem Laboratories rose by 4.95%, to 59.4 Hong Kong dollars; Tigermed rose by 5.21%, to 38.35 Hong Kong dollars; WuXi AppTec rose by 3.69%, to 53.4 Hong Kong dollars.